Form 4: Franklin M. Berger Reports Acquisition of Atea Pharmaceuticals Stock Options and Restricted Stock Units

Director Franklin M. Berger reports acquiring stock options and restricted stock units in Atea Pharmaceuticals.

Summary

• Franklin M. Berger, a director of Atea Pharmaceuticals, reported acquiring 41,200 stock options and 29,600 restricted stock units on June 21, 2024.
• The restricted stock units convert into common stock on a one-for-one basis and vest on the earlier of the next annual meeting or the first anniversary of the grant date, subject to continued service.
• The stock options vest in twelve equal monthly installments following June 21, 2024, and become fully vested on the first anniversary of the grant date, also subject to continued service.
• The exercise price of the stock options is $3.44.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of insider transactions. The acquisition of shares by a director can be seen as a mildly positive signal, but it's not a strong indicator of future performance.

Positives

• The acquisition of stock options and restricted stock units by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedules of the restricted stock units and stock options are contingent on the reporting person's continued service.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the pharmaceutical industry as part of executive compensation packages.

Stakeholder Impact

• The acquisition of shares by a director may have a slightly positive impact on shareholder sentiment.

Key Dates